Walleye Capital
RPRX icon

Walleye Capital’s Royalty Pharma RPRX Stock Holding History

Walleye Capital’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-11,365
Closed -$354K – 4963
2025
Q1 		$354K Sell
11,365
-13,759
-55% -$436K ﹤0.01% 2830
2024
Q4 		$641K Buy
+25,124
New +$666K ﹤0.01% 2778
2024
Q3 		– Sell
-37,635
Closed -$992K – 5781
2024
Q2 		$992K Buy
+37,635
New +$1.04M ﹤0.01% 2858
2023
Q4 		– Sell
-55,104
Closed -$1.5M – 5433
2023
Q3 		$1.5M Buy
55,104
+30,677
+126% +$911K ﹤0.01% 1951
2023
Q2 		$751K Buy
24,427
+2,167
+10% +$73.4K ﹤0.01% 2097
2023
Q1 		$802K Buy
+22,260
New +$825K 0.01% 1323

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
CIA
Caledonia Investments (Australia) Sydney NSW, Australia $2.93B AUM 37.21% 1-Year Est. Return

Walleye Capital's RPRX Position: Q2 2025 in Review

Walleye Capital sold out of Royalty Pharma (RPRX) in Q2 2025, closing a stake of 11,365 shares — an estimated $354K sold.

Walleye Capital first reported a position in RPRX in Q1 2023 and held it in 6 quarters. The position peaked at $1.5M in Q3 2023. 454 funds tracked by Wall St. Rank hold RPRX as of Q2 2025.

  • Walleye Capital reported no remaining Royalty Pharma position as of Q2 2025 after selling out during the quarter.
  • Walleye Capital sold 11,365 Royalty Pharma shares in Q2 2025, an estimated $354K.
  • Walleye Capital first reported a position in Royalty Pharma in Q1 2023 and held it in 6 quarters.
  • Walleye Capital's Royalty Pharma position peaked at $1.5M in Q3 2023.
  • 454 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2025.

Based on Walleye Capital's 13F filing for Q2 2025, filed 13 Aug 2025.